Engflag

Preme

Quick links to important sections

Preme

Preme_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Preme

Property Description
Active ingredient Cyproterone Acetate, Ethinyl Estradiol
Form Oral tablet (coated)
Pharmacological class Antiandrogen-Estrogen Combination (COC)
Common use Counteracting effects of high androgen levels
Origin Synthetic steroid

Preme is a synthetic steroid combination classified as an Antiandrogen-Estrogen Combination, intended for oral administration as a coated tablet. This specific combination is widely clinically recognized for its dual hormonal activity, positioning it as both a specialized treatment for certain hormonal conditions and a highly effective Combined Oral Contraceptive (COC). The drug's core identity involves the systemic modulation of androgens, often referred to generically as Co-cyprindiol.

What Type of Combination Medication is Preme?

Preme is an oral combination product that belongs to the therapeutic class of Antiandrogen-Estrogen Combinations, distinct from standard single-hormone therapies. The medicinal entity is officially classified under the ATC code G03HB01. This combination is available globally under various trade names, highlighting its specialized nature as a progestogen and estrogen combination intended for systemic delivery via the oral route.

Composition: The Role of Cyproterone Acetate and Ethinyl Estradiol

The medicine contains the active ingredients Cyproterone Acetate and Ethinyl Estradiol. Cyproterone Acetate primarily acts as an antiandrogen, blocking receptors for male hormones and suppressing their production. Concurrently, Ethinyl Estradiol, a synthetic estrogen, enhances this action by increasing the levels of Sex Hormone-Binding Globulin (SHBG), which effectively reduces the quantity of free, active androgens circulating in the bloodstream. This pharmacological synergy is supported by research confirming that the combination effectively lowers the impact of male hormones on the body's tissues.

How Does Preme Differ from Standard Contraceptive Pills?

Preme differs from many traditional oral contraceptives because the inclusion of Cyproterone Acetate provides significantly pronounced antiandrogenic activity. This specific combination is an established therapeutic option when other treatments for androgen-dependent symptoms have proven inadequate. This specialization means Preme is typically utilized when the general purpose requires not only reliable contraception but also a specific, powerful effect to counteract the manifestations of androgenization.

Regulatory References

  1. EMA Information on Cyproterone/Ethinyl Estradiol

What side effects are possible with Preme?

Possible side effects and safety information for Preme

Adverse reactions associated with Preme are documented in official regulatory labeling and are categorized by the frequency of occurrence and the affected body system (System-Organ Class).

Common Adverse Reactions

Adverse events reported as Very Common (occurring in 1 in 10 patients or more) or Common (occurring in up to 1 in 10 patients) typically involve systems such as the gastrointestinal tract and the nervous system. Common examples reported in regulatory documents for similar agents include:

  • Gastrointestinal disorders: Nausea, vomiting.
  • Nervous system disorders: Headache, dizziness.
  • General disorders: Flu-like symptoms (often more prominent when treatment is initiated).

Serious and Clinically Significant Adverse Reactions

Regulatory documents highlight reactions that are considered serious or clinically significant, which may necessitate specific monitoring or risk minimization strategies. Although generally less common, these reactions can include:

  • Severe pulmonary issues, such as interstitial pneumonia or Adult Respiratory Distress Syndrome (ARDS), which require immediate medical attention.
  • Hematologic changes, including thrombocytopoenia (low platelet count).
  • Cerebral edema (brain swelling) in rare cases, sometimes associated with hypermethioninemia, typically occurring within the first six months of therapy.

Safety Restrictions and Population Considerations

The official safety information outlines specific contraindications (situations where the drug must not be used) and special warnings and precautions for use. These notes may relate to pre-existing conditions (e.g., severe hepatic or renal impairment) or specific patient groups, such as geriatric or pediatric patients. Additionally, the label may contain statements about dose-related patterns, where the incidence or severity of certain reactions may increase with higher doses.

Overdose and Emergency Response

Overdose Manifestations and Severity

The official regulatory documentation for Preme (Cyproterone Acetate/Ethinyl Estradiol) details the documented manifestations and emergency actions required in the event of an overdose. Acute overdose of this antiandrogen-estrogen combination is generally not expected to produce serious or fatal effects in adult individuals.

The officially documented clinical manifestations are typically limited to nausea and vomiting as primary gastrointestinal symptoms. A hormonal effect known as withdrawal bleeding may also occur in females. The regulatory labeling notes that this manifestation of withdrawal bleeding may specifically occur in pre-pubertal girls if an excessive number of tablets is ingested.

Emergency Actions and Management

If an overdose is suspected, immediate medical attention must be sought for appropriate evaluation and clinical support. Emergency services or a poison control center should be contacted for professional guidance regarding the level of care required.

The official prescribing information explicitly states that no specific antidote is known for an overdose of this combination product. Therefore, the mandated intervention for overdose is symptomatic and supportive treatment based on the patient’s clinical presentation. Hospital monitoring may be required depending on the quantity ingested and the persistence of symptoms. The regulatory profile emphasizes supportive care due to the absence of a known reversal agent.

Therapeutic Uses of Preme

What Preme Treats: Main Uses and Benefits

This specialized combination medicine is considered relevant for addressing specific, pronounced symptoms.

Preme is generally used for the systemic management of moderate to severe androgen-driven symptoms in women of reproductive age. The therapeutic focus is often applied in situations involving persistent manifestations of acne and excessive skin oiliness (seborrhoea) that have not responded adequately to initial treatments, as well as the distressing symptom of hirsutism.

This systemic approach offers support that is relevant for easing symptoms related to abnormal hair growth and may assist in the symptomatic management of persistent skin manifestations. Additionally, it provides a dual therapeutic benefit by simultaneously offering support for the hormone-related skin and hair symptoms and a method of oral contraception.

“This medication is applied in clinical settings that involve chronic or recurrent symptom patterns linked to heightened sensitivity to androgens.”

Quick Fact: Relief for Androgen-Driven Symptoms

Preme is commonly used to help manage severe acne and hirsutism, contributes to easing the overall symptom load related to physical discomfort and supports patients during episodes of heightened discomfort.

Regulatory References

  1. European Medicines Agency (EMA) therapeutic overview

Eligibility and Restrictions for Use

The use of Preme (Cyproterone Acetate/Ethinyl Estradiol) is strictly defined by regulatory documents, making it a specialized treatment intended only for specific populations and contraindicated in numerous health conditions.

Eligibility and Non-Eligibility Status

Population Status Eligibility Criteria (Regulatory Basis)
Use is Allowed Women of reproductive age with moderate to severe androgen-driven symptoms (e.g., severe acne, hirsutism), only after initial treatments (such as topical or systemic antibiotics) have failed.
Absolute Contraindications History of or current meningioma; high risk of venous or arterial thrombotic diseases; diagnosed breast cancer or other estrogen-dependent cancer; active liver disease or liver tumors; undiagnosed abnormal uterine bleeding; and pregnancy.
Conditional Restrictions Must not be used concurrently with any other hormonal contraceptives. Not recommended for use in nursing mothers (lactation) or in women over 35 years of age who smoke.

Age and Comorbidity Rules

Official labeling indicates that Preme is not indicated for use in pre-menarcheal females or postmenopausal (geriatric) women. Furthermore, use is prohibited in patients with uncontrolled hypertension or severe diabetes with vascular changes. The medicine must be immediately discontinued if pregnancy is suspected or confirmed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Preme is primarily characterized by pharmacokinetic interference and formal regulatory restrictions documented in official government labeling.

Contraindicated Combinations and Major Restrictions

Co-administration is formally contraindicated with specific Hepatitis C viral (HCV) medicinal product combinations, including those containing ombitasvir, paritaprevir, and ritonavir. This restriction is required due to the officially documented risk of significant elevations in Alanine Aminotransferase (ALT) levels. Preme is also prohibited for co-administration with any other hormonal contraceptive.

Pharmacokinetic Interference

The effectiveness of Preme can be compromised by co-administration with substances that act as strong hepatic enzyme inducers, particularly of CYP3A4. These enzyme inducers, which include certain anticonvulsant medicines (e.g., phenytoin, carbamazepine) and the herbal product St. John’s Wort, are documented to significantly decrease the plasma concentrations of both Cyproterone Acetate and Ethinyl Estradiol, which officially risks a reduction in contraceptive protection.

Conversely, Preme may inhibit the clearance of other co-administered drugs, leading to increased exposure of those substances. Official labeling notes this potential for increased plasma levels with medicines such as Tizanidine and Cyclosporine. Additionally, a reduction in the plasma concentration of the medicine Lamotrigine is documented upon co-administration. No mandatory administration timing rules are specified in the official regulatory documentation.

Mechanism of Action

The mechanism of action for this combination involves a synchronized dual approach to modulate the body’s androgen signaling system from the point of hormone synthesis to the point of receptor activation. The central mechanism addresses the inhibition of upstream hormone synthesis: the hormonal activity exerts negative feedback inhibition on the Hypothalamic-Pituitary-Ovarian (HPO) Axis, suppressing pituitary gonadotropin release (LH and FSH). This modulation directly leads to a reduction in the ovaries' output of endogenous androgens. Peripherally, the antiandrogen component, Cyproterone Acetate, acts as a competitive antagonist at the Androgen Receptor (AR) in target tissues, directly blocking androgen-mediated cellular signaling. Simultaneously, the estrogen component induces the liver to produce excess Sex Hormone-Binding Globulin (SHBG), which sequesters circulating androgens and reduces the free, bioavailable fraction able to reach those peripheral receptors. This synergy results in a reduction of overall androgen-mediated cellular signaling at the cellular level.

Dosage and Administration Information

How to use Preme: Administration Guidelines

The instructions for using Preme (Cyproterone Acetate and Ethinyl Estradiol) involve a standardized, cyclic regimen to ensure consistent administration and proper cycle management. These guidelines are based on its formulation as an oral coated tablet.

Administration Scope

Feature Description
Route of administration Oral
Dosing schedule One active tablet daily
Timing in relation to meals May be taken independent of food (with or without a meal)
Preparation requirements No preparation or dilution steps are required; take with some liquid as needed

Frequency, Schedule, and Procedural Constraints

Classification Detail
Frequency pattern Daily for 21 days, followed by a 7-day tablet-free interval (Cyclic regimen)
Special procedural conditions The tablet is taken at the same time every day, following the sequential order on the pack.
Missed-dose rules If a dose is delayed by less than 12 hours, the tablet is taken immediately to maintain efficacy.

Connection to the Overall Use Protocol

The protocol involves a 28-day cycle, consisting of the 21-day active tablet regimen and the subsequent tablet-free interval. Treatment duration is governed by specific criteria, usually requiring a course continuation for a minimum of three months to assess response. The medicine is typically withdrawn 3 to 4 cycles after the treated condition has completely resolved, and it is not intended to be continued solely for the purpose of oral contraception.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Preme

Evidence for Use in Moderate to Severe Acne

Clinical evaluation exploring the use of this medicine in the context of moderate to severe acne and excessive skin oiliness (seborrhoea) was primarily conducted through Randomized Controlled Trials (RCTs) and summarized in systematic reviews. These studies focused on women of reproductive age whose symptoms had not adequately improved with initial topical or antibiotic treatments. Researchers monitored key outcomes related to physical discomfort by measuring the number and severity of acne lesions using standardized clinical scoring systems.

Findings describe patterns observed in the studies where trials reported measured changes in the severity of acne and the appearance of skin oiliness over several treatment cycles (typically spanning six to nine months). Research highlights changes measured during the study period by examining data measured in trials that compared it against other active hormonal treatments.

Despite the existence of evidence, certainty about sustained effects remains low regarding the maintenance of these changes after the medicine is stopped. Follow-up durations were limited in many studies, meaning long-term outcomes are not fully established.

Evidence for Use in Hirsutism (Excessive Hair Growth)

Research explored the use of this medicine in the context of hirsutism (excessive unwanted hair growth), and the evidence base includes various Randomized Controlled Trials and systematic reviews. Studies monitored changes in key clinical measurements, such as the Ferriman-Gallwey score, which is a method used by doctors to grade the level of hirsutism. Data show patterns related to measured shifts in these scoring systems across the observed populations.

Research also explored short-term symptom changes by monitoring hormonal shifts, specifically describing measured shifts in biomarkers such as Sex Hormone-Binding Globulin (SHBG) and circulating androgen (male hormone) levels. What is still uncertain is the full scope of long-term outcomes, particularly concerning the patterns of symptom recurrence after treatment is discontinued. Results apply only to the populations studied, and comparative evidence remains limited.

Evidence Quality, Gaps, and Areas of Uncertainty

Official health authorities and scientific reviews utilize this evidence base to determine the indications studied. Key research limitation frames include the fact that follow-up durations were limited, meaning the certainty remains low regarding true long-term effects. Findings describe group patterns, not personal outcomes, and evidence quality varies across studies due to differences in methodologies.

Frequently Asked Questions (FAQ)

Common questions about Preme (FAQ)

Q: Can Preme cause weight gain or loss?

Official regulatory documents and clinical trial data for this type of medicine sometimes report increased weight or weight gain as an adverse reaction. It should be noted that these findings reflect group patterns observed in studies.

Q: Is Preme considered a controlled substance?

This medicine is classified as prescription-only (Rx-only) due to the nature of its active components. However, official information indicates that it is not typically categorized as a federally scheduled controlled substance in the US or Canada because it is not associated with abuse or dependence.

Q: How long has Preme been approved for use?

Combinations containing Cyproterone acetate and Ethinyl Estradiol have been clinically available for many years, with regulatory approval occurring in Europe starting in the mid-1980s and in countries like Canada later in the 1990s. This history indicates a well-established regulatory presence globally, though the specific product, Preme, may not be approved in all regions.

Q: Where can I find the official prescribing information for Preme?

The official detailed information intended for healthcare professionals is published in regulatory documents such as the Summary of Product Characteristics (SmPC) in Europe or the Product Monograph in Canada. These documents include the full details regarding safety, use conditions, and background information.

Q: Is Preme known to be habit-forming?

Official regulatory documents, including the SmPC and Product Monograph, do not classify this medicine as a substance with known potential for abuse or dependence. This means it is not associated with habit-forming behaviors.

Q: Does Preme affect sleep patterns?

Official labeling for this medicine or its components sometimes lists changes in sleep or insomnia as a potential part of central nervous system side effects. Any persistent changes in health or sleep should be discussed with the appropriate healthcare provider.

Q: What are the general rules regarding driving or operating machinery while on Preme?

Official patient information generally notes that the medicine is unlikely to affect your ability to drive or operate machinery. However, official information notes that if side effects such as dizziness occur, performance may be affected.

Q: What is the difference between Preme and a placebo in studies?

Clinical trials often compare this medicine against a placebo (an inactive dummy pill) to measure the magnitude of the medicine's changes on symptoms like acne or excessive hair growth (hirsutism). The medicine is also compared against other active hormonal treatments to understand its effects relative to established options.

Q: Is it possible for Preme to stop working after some time?

Regulatory information primarily focuses on circumstances that can lead to reduced effectiveness. This can happen due to interactions with certain medicines (like strong enzyme inducers) or not consistently taking the medicine as prescribed.

Q: Why is Preme only available by prescription?

This medicine is classified as prescription-only (Rx-only) because it contains active hormonal components and is associated with certain serious health risks, such as the risk of blood clots (venous thromboembolism) and meningioma. The medicine is intended for use under the supervision of a licensed healthcare professional who assesses individual risk factors before prescribing.

Q: Are there any known interactions between Preme and alcohol?

Official regulatory information typically states that alcohol does not directly affect the overall hormonal effectiveness of the medicine itself. However, some official information advises that any substance that may affect cognitive function could impact adherence to the daily dosing schedule.

Q: Does Preme impact fertility or sexual function?

Since the medicine is a hormonal contraceptive, it works by suppressing ovulation and preventing pregnancy while it is in use. Regulatory labeling sometimes lists decreased libido or difficulty becoming pregnant after stopping the medication as adverse effects observed in some patients.

Q: What is the shelf life of Preme if stored correctly?

The official shelf life is defined by the expiration date printed on the packaging, blister foil, or outer carton. This date reflects the time during which the product is guaranteed by the manufacturer to retain its full potency and stability when stored under the recommended conditions.

Q: Why are there different doses of Preme available (general inquiry, not dosing request)?

The availability of different doses is related to the principle of dose minimization. Regulatory reviews often recommend using the lowest possible effective dose to minimize the risk of serious side effects while still providing the required therapeutic effect.

How should Preme be stored and disposed of?

Storage and Disposal Requirements for Preme

The storage and disposal instructions for Preme (Cyproterone Acetate/Ethinyl Estradiol oral tablets) are officially documented to maintain the product's stability and ensure safety.

Official Storage Conditions

Requirement Specification
Temperature Store below 25 C (some regions allow up to 30 C).
Protection Keep protected from light, heat, and moisture.
Packaging Rule Must be kept in the original blister pack and outer carton.
Child Safety Keep the medicine out of sight and reach of children.

Labeled Disposal Rules

Expired or unused Preme tablets must not be discarded in household trash or poured into wastewater. To ensure safe and environmentally sound disposal, regulatory bodies instruct patients to return the unused or expired medicine to a pharmacist or an established local collection point. The product should not be used after the expiration date printed on the package.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Preme found in:

A-Z Index: